Filter
27
Filtered Results: 27
Text search:
Cucunuba,
Z.M.
Featured
New Publications
1
Language
Document type
Studies & Reports
15
Guidelines
9
Situation Updates
1
Fact sheets
1
No document type
1
Countries / Regions
Colombia
6
Latin America and the Carribbean
4
Global
1
Venezuela
1
Middle East and North Africa
1
Brazil
1
Russia
1
Authors & Publishers
Publication Years
Category
Studies & Reports
5
COVID-19
3
Virology
3
Guidelines
2
Toolboxes
Studies & Reports
12
Genomic sequencing
7
Laboratory Guidance
3
Diagnostics & Laboratory Guidance
3
Clinical Aspects & Diagnostics
3
Statistics & Facts
2
Infection Control General
1
Country specific documents
1
Global Impact: Socio-economic, health services, TB & HIV
1
Studies & Reports
1
Prevention & Control
1
Congenital transmission of Chagas disease has not been extensively studied in Colombia, and there are no standardized processes in the health system regarding
the specific diagnosis, treatment and follow-up of this disease. To generate recommendations on congenital Chagas disease and Chagas in wom...
BMJ Glob Health 2017;2:e000345. doi:10.1136/bmjgh-2017-000345. WHO's 2020 milestones for Chagas disease include having all endemic Latin American countries certified with no intradomiciliary Trypanosoma cruzi transmission, and infected patients under care. Evaluating the variation in historical expo...
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
Rev. Panam Salud Publica. 2017;41:e153. doi: 10.26633/RPSP.2017.153
Worldwide, over 6 million people are infected with Trypanosoma cruzi, the pathogen that causes Chagas disease (CD). In the Americas, CD creates the greatest burden in disability-adjusted life years of any parasitic infection. In Co...
WHO-2019-nCoV-genomic_sequencing
Trypanosoma cruzi is the etiological agent of Chagas disease (CD), considered one of the most important parasitic infections in Latin America. Between 25 and 90 million humans are at infection risk via at least one of multiple infection mechanisms. Under natural conditions, the principal transmissio...
Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493
.Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th...
Chagas disease is currently endemic and also predicted to be at increased transmission risk under future climate change scenarios. Similarly, an expansion of areas in the United States at increased risk for Chagas disease transmission is also expected over the next several decades under climate chan...
English Analysis on Brazil about Health, Protection and Human Rights and Epidemic; published on 26 May 2021 by SSHAP
Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga...
Au cours de la dernière décennie, les données de séquençage génétique des agents pathogènes ont gagné en importance et contribuent désormais de façon déterminante à la détection et à la maîtrise des flambées de maladies infectieuses, en facilitant la mise au point de ...
En el último decenio, los datos de las secuencias genéticas de los patógenos han adquirido un papel crucial en la detección y el manejo de los brotes de enfermedades infecciosas, contribuyendo al desarrollo de pruebas diagnósticas, medicamentos y vacunas y orientando la respuesta sanitaria.
The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and programmes. The falling cost and complexity of generating GSD provides opportunities for expanding sequencing capacity; however, challenges to wid...
The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and programmes. The falling cost and complexity of generating GSD provides opportunities for expanding sequencing capacity; however, challenges to wid...
This brief considers the rationale for shielding individuals at high risk of severe disease or death from COVID-19 in low- and middleincome countries. It provides an overview of proposed approaches to shielding, discusses the categories of individuals who may be identified for shielding, and outline...
